Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sanofi (SNY) EBT (2016 - 2026)

Sanofi's EBT history spans 16 years, with the latest figure at $2.7 billion for Q1 2026.

  • On a quarterly basis, EBT rose 2.43% to $2.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $8.9 billion, a 15.6% decrease, with the full-year FY2025 number at $7.2 billion, changed 0.43% from a year prior.
  • EBT hit $2.7 billion in Q1 2026 for Sanofi, up from -$4.9 billion in the prior quarter.
  • Over the last five years, EBT for SNY hit a ceiling of $11.0 billion in Q4 2022 and a floor of -$4.9 billion in Q4 2025.
  • Historically, EBT has averaged $3.4 billion across 5 years, with a median of $2.7 billion in 2026.
  • Biggest five-year swings in EBT: soared 66096.7% in 2022 and later plummeted 380.21% in 2025.
  • Tracing SNY's EBT over 5 years: stood at $11.0 billion in 2022, then fell by 19.44% to $8.9 billion in 2023, then tumbled by 80.19% to $1.8 billion in 2024, then plummeted by 380.21% to -$4.9 billion in 2025, then soared by 154.61% to $2.7 billion in 2026.
  • Business Quant data shows EBT for SNY at $2.7 billion in Q1 2026, -$4.9 billion in Q4 2025, and $9.3 billion in Q3 2025.